XML 45 R2.htm IDEA: XBRL DOCUMENT v2.4.0.8
CONDENSED CONSOLIDATED BALANCE SHEETS (USD $)
In Thousands, unless otherwise specified
Jun. 30, 2013
Dec. 31, 2012
CURRENT ASSETS    
Cash and cash equivalents $ 13,094 $ 16,374
Restricted cash 99 96
Short-term bank deposits 15,015 3,215
Investment in Evogene 4,713 5,196
Other accounts receivable and prepaid expenses 736 690
Total current assets 33,657 25,571
NON-CURRENT INVESTMENTS:    
Long-term lease deposits 22 59
Severance pay fund 1,900 1,728
Total non-current investments 1,922 1,787
LONG-TERM PREPAID EXPENSES 201 301
PROPERTY AND EQUIPMENT, NET 1,226 1,250
Total assets 37,006 28,909
CURRENT LIABILITIES:    
Trade payables 857 443
Other accounts payable and accrued expenses 1,219 941
Total current liabilities 2,076 1,384
NON-CURRENT LIABILITIES:    
Research and development funding arrangements and others 12,037 7,872
Accrued severance pay 2,179 1,981
Total non-current liabilities 14,216 9,853
SHAREHOLDERS' EQUITY (Note 6):    
Ordinary shares of NIS 0.01 par value: 100,000,000 shares authorized at June 30, 2013 and December 31, 2012; 38,361,450 and 36,590,478 shares issued and outstanding at June 30, 2013 and December 31, 2012, respectively 104 99
Additional paid-in capital 216,304 206,325
Accumulated other comprehensive income 4,838 5,367
Accumulated deficit (200,532) (194,119)
Total shareholder' equity 20,714 17,672
Total liabilities and shareholders' equity $ 37,006 $ 28,909